Skip to main content
TB-500 Safe

A welcoming reading room for the TB-500 and Thymosin Beta-4 safety record — what the studies report, and where the human evidence simply is not there yet.

TB-500 Dosage in the Research Literature | TB-500 Safe

The TB-500 dosage data that exists in the peer-reviewed literature is preclinical — rodent intraperitoneal injection studies, equine intramuscular administration, local delivery in fibrin sealant, and one Phase I IV study of the full-length Tβ4 protein (not the TB-500 fragment) in humans [16]. No validated human dose-response study for injectable TB-500 (Ac-LKKTETQ) has been published. What follows is a summary of the doses used in animal research, organized by tissue system and route, for scientific reference.

TB-500 Loading Phase Protocols in Research

Preclinical and equine literature most commonly references administration protocols of 2–5 mg given subcutaneously or intramuscularly, 1–2 times per week, over a 4–6 week period. This protocol is described in equine veterinary contexts where TB-500 (as a veterinary preparation marketed for equine performance) was administered for musculoskeletal conditions, and gave rise to WADA's doping-control methodology for the compound [18].

None of these protocols were validated in a controlled human clinical trial. They are descriptive of practice in the equine research context only. The 4–6 week window appears because most preclinical injury studies use this duration before measuring outcomes — not because it represents an evidence-based 'loading' protocol for any species.

TB-500 Loading Phase Protocols in Research

Preclinical Dose Data by Study

The following doses appear in the peer-reviewed literature for Tβ4 and TB-500 across different study types:

  • 5.37 mg/kg IP — rat cardiac infarction model (Sprague-Dawley, 250–300g); reduced infarct size 43% at 28 days [6]
  • 6 mg/kg or 30 mg/kg IP — rat traumatic brain injury model (young adult male Wistar); 30 mg/kg superior for functional recovery [7]
  • 2–18 mg/kg IP — rat embolic stroke model; optimal calculated at 3.75 mg/kg for day-56 neurological recovery [8]
  • 1 µg local delivery — rat medial collateral ligament (in fibrin sealant at the injury gap); superior biomechanical properties at 4 weeks [9]
  • 150 µg twice weekly IP, 6 months — dystrophin-deficient mice; increased regenerating muscle fibers, no functional improvement [11]
  • 12 mg/kg/day IP, 4 weeks — C57BL/6 mice, NAFLD model; M1→M2 macrophage polarization, reduced hepatic inflammation [22]
  • As low as 10 pg — in vitro keratinocyte migration assays (not a systemic dose; relevant only to cell-level experiments) [3]
  • 0.05–25 µg/kg IV (single dose); 0.5–5.0 µg/kg (10-day multiple dose) — Phase I study of full-length recombinant human Tβ4 (not TB-500 fragment), 54 healthy Chinese volunteers; no serious adverse events [16]

These doses span an enormous range across different species, routes, tissue targets, and preparation types. They do not constitute a dosing guide for any species, including rodents outside the specific protocols cited.

TB-500 Half-Life and Elimination

No validated half-life data exists for the TB-500 fragment (Ac-LKKTETQ) in humans following injectable administration. The available pharmacokinetic data:

Full Tβ4 protein (IV, human): Half-life 0.5–2.08 hours, Tmax 3–15 minutes, following single-dose IV administration in 54 healthy Chinese volunteers in the NL005 Phase I trial [16]. This applies to the full 43-amino-acid protein given intravenously — not the heptapeptide fragment.

TB-500 fragment (rat, injectable): A 2024 study using UHPLC-Q-Exactive Orbitrap MS/MS quantified TB-500 and its metabolites in rat plasma following injection. The primary metabolite Ac-LK peaked at 0–6 hours post-administration; the secondary metabolite Ac-LKK was detectable up to 72 hours. The metabolite Ac-LKKTE showed significant wound-healing activity in fibroblast assays. No cytotoxicity was detected for the parent compound or its metabolites [19].

Based on these datasets, the active window for the fragment in rat plasma likely spans 6–72 hours depending on which metabolite is considered. Human pharmacokinetics for injectable TB-500 remain uncharacterized.

The TB-500 half-life and dosing frequency question — how often TB-500 should be administered based on clearance — cannot be answered from existing published data for humans.

TB-500 Half-Life and Dosing Frequency

Most preclinical dosing references weekly or twice-weekly administration. Daily dosing protocols for TB-500 are not well-represented in the peer-reviewed literature [19]. Higher-frequency dosing without validated safety data represents an uncharacterized risk profile. The question of dosing frequency in humans cannot be answered from the existing literature.

Administration Route: Subcutaneous vs Intramuscular

Most published preclinical studies used intraperitoneal injection — a route unique to small-animal research and not clinically relevant for humans. Subcutaneous and intramuscular administration are referenced in equine and some rodent contexts. No head-to-head human comparison of routes for TB-500 exists in the literature. Both subcutaneous and intramuscular injection are described in equine use contexts, interchangeably, without evidence of differential efficacy or safety.

The full Tβ4 Phase I study used intravenous administration, which is pharmacokinetically distinct from subcutaneous or intramuscular routes used in typical research-peptide protocols [16].

TB-500 Onset: What Animal Models Suggest About Timeline

In rodent wound-healing models, measurable tissue repair effects are typically assessed at 4–7 days (dermal models) [3] or 4 weeks (ligament models) [9], with the compound administered throughout. Rat metabolite data shows detectable active metabolites from 0 to 72 hours after a single injection [19]. Equine data in musculoskeletal conditions references 4–6 week administration protocols before outcome assessment.

No human time-course data for wound healing, injury repair, or any other endpoint exists for TB-500.

TB-500 Cycle Length in Preclinical Protocols

Preclinical studies typically use 4–8 week administration windows aligned to tissue repair endpoints. The 6-month dystrophic mouse study [11] is an outlier for duration and represents a chronic administration model. Longer-term protocols beyond 6 months are not documented in the peer-reviewed literature. No data on repeat-cycle safety — a second course following a gap — exists in any species.

Dosing Frequency: Daily vs Weekly Protocols

Most preclinical dosing is weekly or twice-weekly [11][18][22]. Daily dosing (as in the NAFLD model at 12 mg/kg/day for 4 weeks) [22] appears in specific high-dose chronic protocols. Daily dosing for short-duration human applications is not characterized in any published study. There is no preclinical basis for concluding that daily human dosing is appropriate, safe, or necessary.

Research-Grade TB-500 Purity and Contaminant Risks

A 2023 analytical chemistry study examined internet-marketed TB500/TB1000 products and found composition 'not systematically consistent with its former descriptions' [17]. Contamination risks distinct from the peptide's own pharmacology — bacterial endotoxins, incorrect peptide sequences, undisclosed excipients, heavy metals — represent independent safety hazards in research-grade preparations. The FDA's Category 2 classification of TB-500 specifically cites characterization and impurity concerns as part of its safety rationale.